Aptose Biosciences has two clinical-stage investigational products for hematologic malignancies: CG-806, an oral, first-in-class mutation-agnostic FLT3/BTK inhibitor, and APTO-253, the only clinical stage agent that directly targets the MYC oncogene and inhibits its expression.
Recruiting
This study is being done to evaluate the safety, tolerability and effectiveness of Oral
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas: View Clinical TrialRecruiting
This study is being done to evaluate the safety, tolerability and antitumor activity of oral
A Study of CG-806 in Patients With Relapsed or Refractory Acute Myeloid Leukemia: View Clinical TrialRecruiting
This study is being done to evaluate the safety and effectiveness of APTO-253 for the
A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS: View Clinical TrialFor more information on enrollment in our current clinical trials, please contact us or visit clinicaltrials.gov for location information.
Contact Us Visit ClinicalTrials.gov
The safety and efficacy of the investigational use of these products have not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.